Clin2
NCT06143553Possibly a fitRecruiting

Paclitaxel micelles for metastatic breast cancer

Metastatic Breast Cancer (MBC)

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests a new form of paclitaxel (a chemotherapy drug) for metastatic breast cancer that is HER2-negative. It may be an option if your cancer has returned or not improved after 2 to 4 previous treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
168 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older.
  • Your breast cancer is HER2-negative and has spread to other parts of the body.
  • You have had 2 to 4 prior chemotherapy treatments for metastatic breast cancer.
  • You are willing to provide a biopsy sample or have slides from a previous biopsy.
  • Your cancer can be measured on a scan (like CT or MRI).
  • Your major organs (heart, lungs, liver, kidneys) are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06752811Recruiting· Phase 3
Testing a new paclitaxel formula for advanced pancreatic cancer

This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.

Nanjing, Jiangsu
NCT06496724Recruiting
Study of albumin-bound paclitaxel combo for advanced breast cancer

This study tests a combination of two medicines (albumin-bound paclitaxel and a granulocyte-based therapy) for women with breast cancer that has come back or spread. It may be an option if you have already tried standard treatment and are looking for another approach.

Nanjing, Jiangsu
NCT07602907Recruiting· Phase 2
Low-dose paclitaxel with immunotherapy for advanced HER2-negative breast cancer

This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.

Hangzhou, Zhejiang
NCT06632574Recruiting· Phase 1
Paclitaxel liposomes via artery for advanced solid tumors

This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.

Nanjing
NCT05192798Recruiting· Phase 2
Albumin-bound chemo plus anti-blood-vessel drugs for TNBC

This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.

Bengbu, Anhui
NCT06199895Recruiting· Phase 2
Study of paclitaxel for patients with taxane-resistant solid tumors

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Wuhan, Hubei

Hear when a new Metastatic Breast Cancer (MBC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.